Abstract | OBJECTIVE: To examine the efficacy and toxicity of a moderate dose (250 mg/day) of diethylstilbestrol diphosphate (DES-DP) intravenously administered to patients with hormone refractory prostate cancer (HRPC) as well as the influence of this agent on the endocrine system. PATIENTS AND METHODS: RESULTS: Fourteen patients were eligible. The mean patient age was 75.2 years. With respect to the ECOG pain score, 5 patients scored 1 or higher, in 4 patients, the pain completely disappeared, and in 1 patient, the pain score improved from 4 to 1. The PSA level decreased significantly from 528 +/- 556 ng/ml (mean +/- SD) to 154 +/- 197 ng/ml. The DHEA level was not changed during DES-DP administration. The DHEA-S level decreased significantly from 882 +/- 430 ng/ml to 480 +/- 236 ng/ml. Testosterone and free testosterone were in the castration level before and during the treatment. Toxicity was minimal. None of the patients developed cardiovascular disorder. CONCLUSION: A moderate dose (250 mg/day) of DES-DP decreased PSA levels and relieved pain without causing serious toxicity in patients with HRPC. It is suggested that the mechanism of the DES-DP effect on the decrease in PSA and pain relief involves a decrease in DHEA-S.
|
Authors | Y Takezawa, S Nakata, M Kobayashi, N Kosaku, Y Fukabori, H Yamanaka |
Journal | Scandinavian journal of urology and nephrology
(Scand J Urol Nephrol)
Vol. 35
Issue 4
Pg. 283-7
(Sep 2001)
ISSN: 0036-5599 [Print] England |
PMID | 11676353
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Gonadotropin-Releasing Hormone
- Testosterone
- Dehydroepiandrosterone
- Dehydroepiandrosterone Sulfate
- Diethylstilbestrol
- fosfestrol
|
Topics |
- Adenocarcinoma
(blood, drug therapy)
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Hormonal
(administration & dosage, adverse effects)
- Dehydroepiandrosterone
(blood)
- Dehydroepiandrosterone Sulfate
(blood)
- Diethylstilbestrol
(administration & dosage, adverse effects, analogs & derivatives)
- Gonadotropin-Releasing Hormone
(agonists)
- Humans
- Injections, Intravenous
- Male
- Middle Aged
- Prostatic Neoplasms
(blood, drug therapy)
- Testosterone
(blood)
|